Standard BioTools Inc. Convertible Notes Payable, Noncurrent
Standard BioTools Inc. (LAB) had Convertible Notes Payable, Noncurrent of $54.98 million as of 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities
us-gaap:ConvertibleLongTermNotesPayable · last filed 2023-11-07
- 2023-09-30: Convertible Notes Payable, Noncurrent $54.98M.
- 2023-06-30: Convertible Notes Payable, Noncurrent $54.85M.
- 2023-03-31: Convertible Notes Payable, Noncurrent $54.73M.
- 2022-12-31: Convertible Notes Payable, Noncurrent $54.62M.
| Period end | Convertible Notes Payable, Noncurrent | Convertible Notes Payable, Noncurrent as first filed |
|---|---|---|
| 2023-09-30 | $54.98M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $54.85M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $54.73M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $54.62M 10-Q · filed 2023-11-07 | |
| 2022-09-30 | $54.50M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $54.38M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $54.27M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $54.16M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $54.05M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $53.94M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $53.84M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $54.22M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $54.12M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $54.01M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $53.92M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $53.82M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $49.85M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $49.83M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $49.78M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $172.06M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $169.34M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $166.76M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $164.16M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $195.24M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $195.17M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $195.09M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $195.02M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $194.95M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $194.88M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $194.81M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $194.74M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $194.67M 10-K · filed 2017-03-03 | $195.68M 10-K · filed 2016-02-29 |
| 2015-09-30 | $195.63M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $195.57M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $195.51M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $195.46M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $195.40M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $195.34M 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $195.25M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $0.00 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |